Clinical Trial Update: Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pegylated recombinant human arginase 1 as second-line therapy for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pegylated Recombinant Human Arginase 1

Snippet

Sponsor: Bio-Cancer Treatment International Limited | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED